Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 6
1966 13
1967 20
1968 18
1969 16
1970 26
1971 19
1972 24
1973 26
1974 22
1975 35
1976 18
1977 30
1978 36
1979 36
1980 33
1981 37
1982 44
1983 62
1984 71
1985 82
1986 83
1987 86
1988 97
1989 132
1990 95
1991 121
1992 109
1993 123
1994 133
1995 122
1996 149
1997 135
1998 176
1999 160
2000 199
2001 202
2002 232
2003 275
2004 283
2005 289
2006 340
2007 382
2008 485
2009 499
2010 629
2011 690
2012 791
2013 761
2014 802
2015 789
2016 777
2017 793
2018 862
2019 996
2020 1255
2021 1626
2022 1626
2023 1604
2024 911

Search Results

18,339 results

Results by year

Filters applied: . Clear all
Page 1
Hepatocellular Carcinoma Immunotherapy.
Sperandio RC, Pestana RC, Miyamura BV, Kaseb AO. Sperandio RC, et al. Annu Rev Med. 2022 Jan 27;73:267-278. doi: 10.1146/annurev-med-042220-021121. Epub 2021 Oct 4. Annu Rev Med. 2022. PMID: 34606324 Review.
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.
Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG. Gordan JD, et al. J Clin Oncol. 2020 Dec 20;38(36):4317-4345. doi: 10.1200/JCO.20.02672. Epub 2020 Nov 16. J Clin Oncol. 2020. PMID: 33197225 Clinical Trial.
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W, Tong S, Hu B, Wan T, Tang H, Zhao F, Jiao T, Li J, Zhang Z, Cai J, Ye H, Wang Z, Chen S, Wang Y, Li X, Wang F, Cao J, Tian L, Zhao X, Chen M, Wang H, Cai S, Hu M, Bai Y, Lu S. Zhang W, et al. J Immunother Cancer. 2023 Sep;11(9):e007366. doi: 10.1136/jitc-2023-007366. J Immunother Cancer. 2023. PMID: 37730273 Free PMC article. Clinical Trial.
18,339 results
You have reached the last available page of results. Please see the User Guide for more information.